LOM
NKTR icon

Loeb Offshore Management’s Nektar Therapeutics NKTR Stock Holding History

Loeb Offshore Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,877
Closed -$320K – 205
2013
Q4 		$320K Buy
+1,877
New +$303K 0.09% 148
2013
Q3 		– Sell
-1,133
Closed -$196K – 243
2013
Q2 		$196K Buy
+1,133
New +$174K 0.1% 118

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loeb Offshore Management's NKTR Position: Q1 2014 in Review

Loeb Offshore Management sold out of Nektar Therapeutics (NKTR) in Q1 2014, closing a stake of 1,877 shares — an estimated $320K sold.

Loeb Offshore Management first reported a position in NKTR in Q2 2013 and held it in 2 quarters. The position peaked at $320K in Q4 2013. 138 funds tracked by Wall St. Rank hold NKTR as of Q1 2014.

  • Loeb Offshore Management reported no remaining Nektar Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Loeb Offshore Management sold 1,877 Nektar Therapeutics shares in Q1 2014, an estimated $320K.
  • Loeb Offshore Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 2 quarters.
  • Loeb Offshore Management's Nektar Therapeutics position peaked at $320K in Q4 2013.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2014.

Based on Loeb Offshore Management's 13F filing for Q1 2014, filed 15 May 2014.